Docoh
Loading...

ABMD Abiomed

Abiomed is a publicly-traded medical devices company that develops and manufactures the circulatory support device Impella, the world’s smallest heart pump. The company is headquartered in Danvers, Massachusetts and has three additional offices, two in Germany in the cities of Berlin and Aachen, and another in Tokyo, Japan. Michael R. Minogue is Chairman, CEO & President of the company, with Dr. Thorsten Siess as Chief Technology Officer, Dr. Chuck Simonton as Chief Medical Officer and Dr. David M. Weber as Chief Operating Officer. According to Bloomberg, the company "engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients". As of 2019, the company had secured five FDA approvals and 715 patents with 622 pending. For fiscal year 2019, Abiomed reported $769.4 million in revenue and reported diluted earnings per share was $5.61 for the year. Abiomed was founded in Danvers, Massachusetts by David M. Lederman in 1981 as Applied Biomedical Corporation. That year, the company commenced the development of an artificial heart. Funded by federal research grants, Lederman partnered with The Texas Heart Institute to develop the AbioCor, a grapefruit-sized electromagnetic device with an internal battery that completely replaces the heart without wires or tubes passing through the skin. In July 2001, AbioCor became the first artificial heart successfully implanted in a patient, where it pumped more than 20 million times. Fourteen of the AbioCor devices were implanted, during clinical trials from 2001 to 2004, with the longest-living recipient surviving 512 days. The AbioCor won FDA approval in 2006 for patients who are near death and do not qualify for a heart transplant.

Company profile

Ticker
ABMD
Exchange
CEO
Michael Minogue
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
42743260

ABMD stock data

(
)

Calendar

4 Feb 21
11 Apr 21
31 Mar 22
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Mar 20 Mar 19 Mar 18 Mar 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Abiomed earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 181.02M 181.02M 181.02M 181.02M 181.02M 181.02M
Cash burn (monthly) 7.07M (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn)
Cash used (since last report) 23.87M n/a n/a n/a n/a n/a
Cash remaining 157.15M n/a n/a n/a n/a n/a
Runway (months of cash) 22.2 n/a n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
31 Mar 21 Minogue Michael R Common Stock $.01 par value Grant Aquire A No No 0 52 0 210,853
31 Mar 21 Greenfield Andrew J Common Stock, $.01 par value Grant Aquire A No No 0 30 0 36,960
17 Feb 21 Myron L Rolle Common Stock, $0.01 par value Grant Aquire A No No 0 790 0 790
17 Feb 21 Sutter Martin P Common Stock, $0.01 par value Sell Dispose S No Yes 314.01 3,750 1.18M 176,510
16 Feb 21 Sutter Martin P Common Stock, $0.01 par value Sell Dispose S No Yes 330.67 3,750 1.24M 180,260

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13.5% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 3 162 -98.1%
Opened positions 0 42 EXIT
Closed positions 159 15 +960.0%
Increased positions 1 55 -98.2%
Reduced positions 2 37 -94.6%
13F shares
Current Prev Q Change
Total value 631.9M 2.3B -72.6%
Total shares 6.09M 30.44M -80.0%
Total puts 0 86K EXIT
Total calls 0 237.1K EXIT
Total put/call ratio 0.4
Largest owners
Shares Value Change
TROW T. Rowe Price 2.48M $257.31M +6.4%
Gilder Gagnon Howe & Co 1.86M $193.15M -1.1%
JPM JPMorgan Chase & Co. 1.75M $181.44M -6.1%
Largest transactions
Shares Bought/sold Change
FMR 0 -5.1M EXIT
BLK Blackrock 0 -2.27M EXIT
Vanguard 0 -2.23M EXIT
WFC Wells Fargo & Co. 0 -1.46M EXIT
Alpine Global Management 0 -1.07M EXIT
Point72 Asset Management 0 -700.23K EXIT
STT State Street 0 -657.3K EXIT
Wellington Management 0 -596.09K EXIT
Capital World Investors 0 -585K EXIT
Jennison Associates 0 -582.93K EXIT

Financial report summary

?
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: adjacent, administered, anxiety, bore, closure, detection, earlier, EFS, essentially, flexible, Fr, French, indefinite, land, lived, mix, momentarily, nitinol, onsite, population, PPE, produce, retention, site, translation, trauma, vaccinated
Removed: adversely, categorized, commercialization, disease, Enterprise, initial, participant, representative, reviewed, settlement, Wide

Patents

APP
Utility
Cleaning System for Diaphragm Pump
8 Apr 21
Apparatus and methods for cleaning a single-port fluidic device, such as a single-port, diaphragm-based cardiac pump, with a continuous stream of fresh cleaning fluid, while simultaneously draining soiled fluid, via a single input-output port of the fluidic device.
GRANT
Utility
Expandable introducer sheath for medical device
6 Apr 21
An expandable medical sheath can include a sheath body having a lumen that extends between proximal and distal ends of the sheath.
APP
Utility
Malleable Sheath Body
1 Apr 21
A blood pump assembly includes an introducer sheath with a proximal end and a distal end, a pump body which extends within the introducer sheath, and a catheter that interfaces with the pump body and extends proximally though the introducer sheath.
APP
Utility
Collapsible Catheter
1 Apr 21
An intravascular system includes an introducer sheath with fixed-diameter lumen, a medical device, and a catheter with a proximal end and a distal end coupled to the first medical device.
GRANT
Utility
Catheter device comprising a separating device for retaining magnetic particles contained in a fluid and protection device for a functional element
30 Mar 21
A catheter device having a catheter (24) in which a rotating shaft (25) which is made at least partially from a magnetic material is arranged, and a separating device which contains an annular body (27) surrounding the rotating shaft and having a cavity containing a magnetic body (13′), the magnetic body being arranged downstream from a point at which the shaft (25) exits the catheter (24) which it surrounds with respect to the direction of flow of the fluid through the catheter.